Next quarter’s earnings estimate for AUPH is -$0.02 with a range of -$0.09 to $0.16. The previous quarter’s EPS was $0.10. AUPH beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.15% of the time in the same period. In the last calendar year AUPH has Outperformed its overall industry.

AUPH Sales Forecast

Next quarter’s sales forecast for AUPH is $60.11M with a range of $57.75M to $60.81M. The previous quarter’s sales results were $67.77M. AUPH beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.81% of the time in the same period. In the last calendar year AUPH has Outperformed its overall industry.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stacy Ku

TD Cowen

$11

Buy

40.49%

Upside

Reiterated

11/19/24

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (NASDAQ: AUPH) and Siemens Healthineers AG (Other OTC: SEMHF)

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

11/18/24

Positive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis Guidelines

David Martin PhD

Bloom Burton

$10.85

Buy

38.57%

Upside

Reiterated

11/11/24

3 Best Stocks to Buy Now, 11/11/2024, According to Top Analysts - TipRanks.comAurinia Pharmaceuticals (AUPH) This biopharmaceutical company develops therapies for autoimmune diseases, particularly lupus nephritis. Today, Bloom Burton analyst David Martin, PhD, maintained a Buy rating on the stock with a price target of $10.85. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 44%.

Douglas Miehm

RBC Capital

Buy

14.94%

Upside

Assigned

11/10/24

Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital

Ed Arce

H.C. Wainwright

$13

Buy

66.03%

Upside

Reiterated

09/05/24

Buy Rating Affirmed for Aurinia Pharmaceuticals on AUR200's Clinical and Financial Promise

Maury Raycroft

Jefferies

$9→$6

Hold

-23.37%

Downside

Reiterated

05/02/24

Aurinia Pharmaceuticals (AUPH) PT Lowered to $6 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $6.00 (from $9.00) while maintaining a Hold rating.

Olivia Brayer

Cantor Fitzgerald

$12→$10

Buy

27.71%

Upside

Reiterated

02/23/24

Aurinia Pharmaceuticals (AUPH) PT Lowered to $10 at Cantor FitzgeraldCantor Fitzgerald analyst Olivia Brayer lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $10.00 (from $12.00) while maintaining a Overweight rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aurinia Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy AUPH and Sell After:

1 Month

xxx

Success Rate

20/32 ratings generated profit

Average Return

+11.85%

assigned a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +11.85% per trade.

3 Months

xxx

Success Rate

14/32 ratings generated profit

Average Return

+13.96%

assigned a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of +13.96% per trade.

1 Year

David Martin PhDBloom Burton

Success Rate

12/21 ratings generated profit

Average Return

+29.98%

reiterated a buy rating 3 months ago

Copying David Martin PhD's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +29.98% per trade.

2 Years

xxx

Success Rate

11/21 ratings generated profit

Average Return

+34.04%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.38% of your transactions generating a profit, with an average return of +34.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AUPH Analyst Recommendation Trends

Rating

Mar 24

May 24

Aug 24

Sep 24

Nov 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AUPH has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AUPH average Analyst price target in the past 3 months is $11.00.

Each month's total comprises the sum of three months' worth of ratings.

AUPH Stock Forecast FAQ

What is AUPH’s average 12-month price target, according to analysts?

Based on analyst ratings, Aurinia Pharmaceuticals’s 12-month average price target is $11.00.

What is AUPH’s upside potential, based on the analysts’ average price target?

Aurinia Pharmaceuticals has 40.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AUPH a Buy, Sell or Hold?

Aurinia Pharmaceuticals has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.

What is Aurinia Pharmaceuticals’s price target?

The average price target for Aurinia Pharmaceuticals is $11.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 40.49% Increase from the current price of $7.83.

What do analysts say about Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.

How can I buy shares of AUPH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

AUPH Financial Forecast

AUPH Earnings Forecast

AUPH Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering Aurinia Pharmaceuticals

AUPH Analyst Recommendation Trends

AUPH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts